| Field | Specification |
|---|---|
| Target | |
| Alternative names | Rap guanine nucleotide exchange factor 3; Exchange factor directly activated by cAMP 1; Exchange protein directly activated by cAMP 1; EPAC 1; Rap1 guanine-nucleotide-exchange factor directly activated by cAMP; cAMP-regulated guanine nucleotide exchange factor I; cAMP-GEFI; RAPGEF3; CGEF1; EPAC; EPAC1 |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthesized peptide derived from human Epac1 The activation of RaP1 by cAMP is independent of PKA and is mediated by recently discovered family of guanine nucleotide exchange factors (GEFs) called cAMP-GEFs or Epacs. The Epac signaling therefore represents a novel mechanism for cAMP signaling with in the cAMP cascade. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone AEOG-18 is a rabbit monoclonal antibody that recognizes rap guanine nucleotide exchange factor 3 (gene RAPGEF3) in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF and immunoprecipitation. The predicted molecular weight is 103.8 kDa, and the supplier reports an observed band at about 104 kDa.
EPAC1 (RAPGEF3) is a cAMP-activated guanine nucleotide exchange factor for Rap1 and Rap2. It provides a PKA-independent route for cAMP signaling and regulates cell adhesion, endothelial barrier function and secretion, and it is studied in cardiovascular and metabolic research.
| Target | Rap guanine nucleotide exchange factor 3 (gene RAPGEF3; UniProt O95398, human) |
|---|---|
| Clone | AEOG-18 |
| Host / Clonality / Isotype | Rabbit / Monoclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Liquid |
| Formulation | PBS (pH 7.4); 150 mM NaCl; 0.02% sodium azide; 50% glycerol; plus stabilizers |
| Calculated MW | 103.8 kDa |
| Observed MW | 104 kDa |
| Storage | Long term: −20 °C for up to 12 months. Frequent use: 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 1:500–1:2000 |
|---|---|
| Immunohistochemistry | 1:50–1:200 |
| Immunocytochemistry / Immunofluorescence | 1:50–1:200 |
| Immunoprecipitation | 1:50 |
Samples with a confirmed band (WB): human HUVEC cells, rat brain tissue, rat kidney tissue, mouse brain tissue, mouse kidney tissuebrIHC: mouse brain tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 1:500 overnight at 4 °C, HRP-conjugated secondary antibody at 1:500, ECL detection.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Immunogen
Synthetic peptide based on the sequence of human epac1.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places rap guanine nucleotide exchange factor 3 in the endomembrane system. Tissue expression noted by UniProt (human): Widely expressed with highest levels in adult kidney, heart, thyroid and brain, and fetal kidney. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Xin Zhou et al. (2025) Protein Kinase Inhibitor Alpha Drives Vincristine Resistance in Ewing Sarcoma via cAMP–EPAC Signaling Reprogramming. Molecular Carcinogenesis. 10.1002/mc.70065
